European Ex-Factory Price Development for Global Pharmaceutical Companies in the Context of the International Price Reference (Ipr) Framework. Impact of the German Health Care Reform (Amnog) on the European Price Development for Innovative Pharmaceuticals

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.03.1232
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Development of Drug Price Index for Each Health Care Sector in Taiwan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Assesing the Impact of Patent Loss on Overall Revenues and Stocks Price of Pharmaceutical Companies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Apartment Price Models for the Glenwood Riverfront Development

Oregon Undergraduate Research Journal
2013English

International Best Practices for Negotiating 'Reimbursement Contracts' With Price Rebates From Pharmaceutical Companies

Health Affairs
MedicineHealth Policy
2013English

Price Negotiation for Pharmaceuticals in Germany: High Influence of Eu Price Weighting Method

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

The Pharmaceutical Price Regulation Scheme

BMJ
2007English

The Impact of Price Perception on Customer Loyalty in the Airline Context

Journal of Business & Economics Research (JBER)
2011English

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending

SSRN Electronic Journal
2006English

PHP149 Perception of Pharmaceutical Companies on the Drug Price-Volume Negotiation in South Korea

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy